Fmr LLC lowered its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 3.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,087,997 shares of the biotechnology company’s stock after selling 34,000 shares during the period. Fmr LLC owned about 1.98% of Sarepta Therapeutics worth $36,676,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in SRPT. Principal Financial Group Inc. raised its holdings in Sarepta Therapeutics by 1.4% in the 1st quarter. Principal Financial Group Inc. now owns 9,455 shares of the biotechnology company’s stock worth $280,000 after purchasing an additional 129 shares in the last quarter. Legal & General Group Plc raised its holdings in Sarepta Therapeutics by 3.9% in the 2nd quarter. Legal & General Group Plc now owns 17,590 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 663 shares in the last quarter. Rhumbline Advisers raised its holdings in Sarepta Therapeutics by 2.3% in the 2nd quarter. Rhumbline Advisers now owns 61,462 shares of the biotechnology company’s stock worth $2,072,000 after purchasing an additional 1,383 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Sarepta Therapeutics by 0.8% in the 1st quarter. Bank of New York Mellon Corp now owns 247,924 shares of the biotechnology company’s stock worth $7,339,000 after purchasing an additional 1,923 shares in the last quarter. Finally, Stifel Financial Corp raised its holdings in Sarepta Therapeutics by 19.3% in the 1st quarter. Stifel Financial Corp now owns 13,366 shares of the biotechnology company’s stock worth $397,000 after purchasing an additional 2,165 shares in the last quarter. 65.41% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Fmr LLC Has $36.68 Million Holdings in Sarepta Therapeutics, Inc. (SRPT)” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/fmr-llc-has-36-68-million-holdings-in-sarepta-therapeutics-inc-srpt/1642743.html.

In other Sarepta Therapeutics news, SVP Shamim Ruff sold 11,500 shares of the business’s stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $50.00, for a total value of $575,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Douglas S. Ingram bought 47,058 shares of Sarepta Therapeutics stock in a transaction on Thursday, July 27th. The stock was purchased at an average price of $42.50 per share, with a total value of $1,999,965.00. Following the completion of the acquisition, the chief executive officer now directly owns 382,058 shares of the company’s stock, valued at approximately $16,237,465. The disclosure for this purchase can be found here. Insiders own 9.60% of the company’s stock.

Shares of Sarepta Therapeutics, Inc. (NASDAQ SRPT) opened at 50.72 on Friday. Sarepta Therapeutics, Inc. has a 1-year low of $26.26 and a 1-year high of $52.67. The company’s market capitalization is $3.26 billion. The firm’s 50-day moving average is $47.21 and its 200-day moving average is $37.70.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.92) by $0.46. The firm had revenue of $35.01 million during the quarter, compared to the consensus estimate of $22.52 million. The business’s revenue for the quarter was up 350000.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.19) earnings per share. Analysts forecast that Sarepta Therapeutics, Inc. will post ($1.16) earnings per share for the current fiscal year.

Several research analysts have commented on SRPT shares. SunTrust Banks, Inc. restated a “buy” rating on shares of Sarepta Therapeutics in a report on Thursday, July 20th. Credit Suisse Group set a $64.00 price objective on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a report on Tuesday, July 18th. Leerink Swann restated a “buy” rating and issued a $60.00 price objective (up from $52.00) on shares of Sarepta Therapeutics in a report on Tuesday, July 18th. BidaskClub upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Finally, Royal Bank Of Canada restated a “buy” rating and issued a $60.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, June 22nd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and sixteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $64.34.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.